SCYNEXIS Unveils Potent New Weapon Against Fungal Superbugs

JERSEY CITY, NJ – January 28, 2026 – As global health leaders convene in Las Vegas for the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), biotechnology firm SCYNEXIS is stepping into the spotlight with potentially game-changing data on its next-generation antifungal drug candidate, SCY-247. The company announced it will present findings that highlight the drug's potent activity against some of the world's most dangerous and drug-resistant fungal pathogens, offering a new ray of hope in a rapidly escalating public health crisis.

The presentations, scheduled for an oral plenary session and a poster display at the joint conference of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), are expected to detail the significant progress of SCY-247. This novel agent belongs to a unique class of drugs known as “fungerps,” pioneered by SCYNEXIS.

“The potent in vitro and in vivo antifungal activity of our second-generation fungerp, SCY-247, together with the favorable safety profile and pharmacokinetics observed in clinical investigations to date, position this novel agent as a potentially critical weapon in the fight against deadly fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. He emphasized the timeliness of the conference, given the “growing recognition of the serious impact to human health posed by antifungal resistance.”

The Growing Shadow of Fungal Superbugs

The urgency for new antifungal agents like SCY-247 cannot be overstated. Often overshadowed by bacterial resistance, drug-resistant fungal infections have become a silent, creeping pandemic. In the United States alone, fungal diseases are linked to an estimated 7,300 deaths, over 130,000 hospitalizations, and staggering annual costs that may approach $48 billion when considering total societal impact.

At the forefront of this threat is Candida auris, a multidrug-resistant yeast that the Centers for Disease Control and Prevention (CDC) has labeled an “alarming” threat. This pathogen can cause severe, invasive infections with high mortality rates and is notoriously difficult to eradicate from healthcare settings. Worryingly, resistance to common antifungal treatments is on the rise. Data shows that resistance of C. auris to fluconazole, a first-line antifungal, has skyrocketed from nonexistent just a few years ago to affecting over 40% of isolates by 2022.

This crisis is not limited to a single pathogen. The World Health Organization (WHO) has published its own fungal priority pathogen list, highlighting other species like Candida glabrata and Candida parapsilosis that are developing resistance to existing therapies, leaving clinicians with dangerously few options for vulnerable patients, such as those undergoing chemotherapy, organ transplants, or in intensive care units.

A New Class of Weapons: The 'Fungerp' Platform

SCY-247 emerges from SCYNEXIS's proprietary 'fungerp' platform, a novel class of triterpenoid antifungals that attack fungi in a unique way. These drugs work by inhibiting glucan synthase, an enzyme essential for building the fungal cell wall. Without a stable cell wall, the fungus cannot survive, leading to a potent, fungicidal effect. While another class of drugs, the echinocandins, also targets this enzyme, fungerps bind to a different site. This crucial difference allows them to remain effective against many fungal strains that have already developed resistance to echinocandins.

This distinct mechanism provides a critical advantage. It means that fungerps like SCY-247 can potentially overcome resistance that has rendered other drugs useless. Furthermore, because mammalian cells do not have cell walls, this targeted approach results in a favorable safety profile with fewer “off-target” effects on the human body. The fungerp class also offers superior flexibility, with formulations being developed for both oral and intravenous (IV) administration. This allows for a seamless transition from hospital-based IV treatment to oral therapy at home, a significant advantage over the IV-only echinocandins.

SCY-247: From Lab to Clinic

SCY-247 is the company's second-generation fungerp, building on the success of its predecessor, ibrexafungerp (marketed as BREXAFEMME®). While BREXAFEMME broke new ground and secured FDA approval for treating vaginal yeast infections, SCY-247 is being developed for more severe, life-threatening invasive fungal infections.

The drug has already successfully completed a Phase 1 study for its oral formulation, demonstrating a favorable safety and tolerability profile. Early data suggests it can achieve effective concentrations in the body at lower doses than the first-generation compound, which could further enhance its safety. SCYNEXIS is now advancing the program, with plans to initiate a Phase 2 study of the oral drug for invasive candidiasis and a Phase 1 study for an intravenous formulation in 2026.

Recognizing its potential, the FDA granted SCY-247 both Qualified Infectious Disease Product (QIDP) and Fast Track designations on January 21, 2026. These designations are critical for expediting the drug's development and review process. The Fast Track status enables more frequent communication with the FDA, while the QIDP designation, part of the GAIN Act, provides an additional five years of market exclusivity upon approval—a powerful incentive for companies tackling the high-risk, high-cost challenge of antimicrobial development.

SCYNEXIS's Strategic Play in a High-Stakes Market

The development of SCY-247 is a key pillar in SCYNEXIS's long-term strategy to become a leader in the anti-infective space. The company has already demonstrated its ability to bring a novel fungerp from discovery to market with ibrexafungerp. The subsequent licensing of BREXAFEMME's commercial rights to pharmaceutical giant GSK in a deal that included significant payments and future royalties has provided a strategic capital infusion and validation of the platform's value.

With that asset now in the hands of a global commercial partner, SCYNEXIS has pivoted its focus to the significant unmet need in invasive fungal infections with SCY-247. As of its last reporting period, the company held $37.9 million in cash and equivalents, which it is deploying to advance its pipeline. While the company has faced challenges, including a Nasdaq notice regarding its minimum bid price, the clinical and regulatory progress of SCY-247 represents a powerful value driver.

The data presented at IMARI this week will be closely watched by clinicians, public health officials, and investors alike. It represents a critical milestone not only for SCYNEXIS but for the entire field of infectious disease, offering a tangible advancement in a fight where new weapons are desperately needed.